PMID: 6161895Nov 1, 1980Paper

The antihypertensive effect of captopril. Evidence for an influence of kinins

Hypertension
A MimranB Laroche

Abstract

The acute effect of the orally-active converting enzyme inhibitor, captopril, was compared to that of saralasin in 13 patients with various forms of hypertension on ad libitum sodium intake. A significant difference between the effects of the two drugs on mean arterial pressure (MAP) was found (-11 +/- 3 mm Hg with saralasin, -24 +/- 4.5 mm Hg after captopril). This difference was not correlated with control plasma renin activity (PRA). To determine the influence of the endogenous kallikrein-kinin system in the antihypertensive action of captopril, the effect of aprotinin (Apro), an inhibitor of kinin generation, on the MAP level achieved by captopril was assessed in five normal subjects and 15 patients with hypertension on ad libitum sodium intake. In normal subjects, captopril did not alter MAP, nor did Apro have any effect. In six patients with essential hypertension and normal PRA, MAP decreased by 5.5 +/- 2 mm Hg following captopril, and Apro did not modify this level. In nine patients with renovascular hypertension (RVH), MAP fell by 22 +/ 3 mm Hg after captopril administration, and Apro infusion induced a rise in MAP of 13 +/- 1.7 mm Hg. A positive correlation between log control PRA and the effect of aprotinin was obtai...Continue Reading

References

May 31, 1976·The American Journal of Medicine·E G Erdös
Jul 28, 1977·The New England Journal of Medicine·G H Williams, N K Hollenberg
Nov 3, 1979·British Medical Journal·A J Man in 't VeldM A Schalekamp
May 1, 1974·Kidney International·A MimranN K Hollenberg
Dec 1, 1968·The Biochemical Journal·J W RyanJ M Stewart
Sep 23, 1967·Nature·H Y Yang, E G Erdös

❮ Previous
Next ❯

Citations

Jul 15, 1983·Clinica Chimica Acta; International Journal of Clinical Chemistry·F M DuncanC R Edwards
Jul 4, 1995·European Journal of Pharmacology·K L ClarkG M Drew
Mar 1, 1996·Journal of the American College of Cardiology·J J MilavetzS Goldman
Jul 1, 1985·Clinical and Experimental Pharmacology & Physiology·G R Bolt, P R Saxena
Aug 20, 1984·The American Journal of Medicine·C S SweetL G Ribeiro
Apr 6, 2002·Expert Opinion on Pharmacotherapy·J David Spence
Jan 1, 1986·Clinical and Experimental Hypertension. Part A, Theory and Practice·K ChimoriK Miura
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·S MatsukawaT Saruta
Jan 1, 1985·Clinical and Experimental Hypertension. Part A, Theory and Practice·F J SalazarT Quesada
Jan 1, 1984·Clinical and Experimental Hypertension. Part A, Theory and Practice·M KogureK Murata
May 1, 1992·The American Journal of the Medical Sciences·C Arzubiaga, N A Beck
Dec 1, 1982·Kidney International
Apr 1, 1987·Kidney International·R G Luke
Jan 1, 1985·Pharmacological Research Communications·G G Orce, G A Castillo
Oct 1, 1990·International Journal of Cardiology·A A Ajayi, M O Balogun
Aug 1, 1984·Journal of Clinical Pharmacology·K L Duchin, D A Willard
Jan 1, 1982·British Journal of Clinical Pharmacology·A Mimran, B Jover
Sep 27, 1985·The American Journal of Medicine·G H Williams, N K Hollenberg
Apr 15, 1988·The American Journal of Medicine·N K Hollenberg
Dec 8, 1988·The New England Journal of Medicine·G H Williams
Mar 1, 1995·Clinical Pharmacology and Therapeutics·N D Fisher, N Hollenberg
Oct 1, 1987·European Journal of Clinical Investigation·K W JauchG Dietze

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.